<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22997">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02807402</url>
  </required_header>
  <id_info>
    <org_study_id>P15-698</org_study_id>
    <nct_id>NCT02807402</nct_id>
  </id_info>
  <brief_title>Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania</brief_title>
  <official_title>Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Romania</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IST GmbH, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to provide evidence of the effectiveness and obtain patient reported
      outcome (PRO) data for the interferon-free ABBVIE REGIMEN ± RBV in participants with chronic
      hepatitis C (CHC) in a real life setting across clinical practice patient populations in
      Romania
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants achieving sustained virological response 12 weeks post-treatment (SVR12)</measure>
    <time_frame>12 weeks (i.e. at least 70 days) after the last dose of study drug</time_frame>
    <description>SVR12 defined as the hepatitis C virus (HCV) ribonucleic acid (RNA) level less than 50 IU/mL 12 weeks after the last dose of study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Usage pattern of treatment regimen in Romania</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Evaluate the usage pattern of treatment regimen type (± Dasabuvir, ± RBV, intended and actual combination, dose and duration) in the Romanian population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the direct-acting antiviral (DAA) dose taken in relation to the target dose of DAA</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the Ribavirin (RBV) dose taken in relation to the target dose of RBV</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of missed Ribavirin (RBV) treatment days in relation to the target number of RBV treatment days</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with concomitant medications</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with co-morbidities</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in participants workability measured with the Work Productivity and Activity Impairment (WPAI):Hepatitis C questionnaire</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in participants quality of life measured with the EuroQol 5 dimension 5 level (EQ-5D-5L) questionnaire</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of participant activation with the Patient activation Measure (PAM-13) questionnaire</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants with virological response at end of treatment (EoT).</measure>
    <time_frame>Up to EoT, maximum of 24 weeks</time_frame>
    <description>Virological response defined as HCV RNA level less than 50 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants with relapse at EoT</measure>
    <time_frame>Up to EoT, maximum of 24 weeks</time_frame>
    <description>Relapse defined as HCV RNA less than 50 IU/mL at EoT followed by HCV RNA greater than or equal to 50 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants with breakthrough.</measure>
    <time_frame>Up to EoT, maximum of 24 weeks</time_frame>
    <description>Breakthrough defined as at least 1 documented HCV RNA less than 50 IU/mL followed by HCV RNA greater than or equal to 50 IU/mL during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants meeting on-treatment virologic failure.</measure>
    <time_frame>12 weeks (i.e. at least 70 days) after the last dose of study drug</time_frame>
    <description>On-treatment virologic failure defined as breakthrough (at least
1 documented HCV RNA less than 50 IU/mL followed by HCV RNA greater than or equal to 50 IU/mL during treatment) or failure to suppress (each measured on-treatment HCV RNA value greater than or equal to 50 IU/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of participants meeting premature study drug discontinuation.</measure>
    <time_frame>12 weeks (i.e. at least 70 days) after the last dose of study drug</time_frame>
    <description>Defined as participants who prematurely discontinued study drug and who experienced no on-treatment virologic failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants meeting missing SVR12 data and/or none of the above criteria.</measure>
    <time_frame>12 weeks (i.e. at least 70 days) after the last dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Patients with chronic infection of HCV Genotype 1 (GT1)</arm_group_label>
    <description>Treatment-naïve or -experienced adult male or female patients with confirmed CHC, genotype 1 , receiving combination therapy with the interferon-free ABBVIE REGIMEN± RBV according to standard of care and in line with the current local label</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic infection of HCV Genotype 1 (GT1)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Treatment-naïve or -experienced adult male or female patients with confirmed CHC, genotype
        1 , receiving combination therapy with the interferon-free ABBVIE REGIMEN± RBV according
        to standard of care and in line with the current local label

        If RBV is co-administered with the ABBVIE REGIMEN, it has been prescribed in line with the
        current local label (with special attention to contraception requirements and
        contraindication during pregnancy)

        Patients must voluntarily sign and date a patient authorization to use and/or disclose
        his/her anonymized health data prior to inclusion into the study

        Patient must not be participating or intending to participate in a concurrent
        interventional therapeutic trial

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corina Ionescu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbvie Romania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154186</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154188</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152384</name>
      <address>
        <city>Bucharest</city>
        <zip>20475</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152376</name>
      <address>
        <city>Bucharest</city>
        <zip>21105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152385</name>
      <address>
        <city>Bucharest</city>
        <zip>21105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152386</name>
      <address>
        <city>Bucharest</city>
        <zip>21105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152390</name>
      <address>
        <city>Bucharest</city>
        <zip>21105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154187</name>
      <address>
        <city>Bucharest</city>
        <zip>21105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152387</name>
      <address>
        <city>Bucharest</city>
        <zip>22328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152388</name>
      <address>
        <city>Bucharest</city>
        <zip>22328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153377</name>
      <address>
        <city>Bucharest</city>
        <zip>22328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152367</name>
      <address>
        <city>Bucharest</city>
        <zip>30223</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152383</name>
      <address>
        <city>Bucharest</city>
        <zip>30303</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152389</name>
      <address>
        <city>Bucharest</city>
        <zip>30303</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152381</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152380</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400375</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152382</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>410072</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152368</name>
      <address>
        <city>Constanta</city>
        <zip>900635</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152371</name>
      <address>
        <city>Constanta</city>
        <zip>900697</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152379</name>
      <address>
        <city>Constanta</city>
        <zip>900709</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152378</name>
      <address>
        <city>Iasi</city>
        <zip>700463</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152375</name>
      <address>
        <city>Iasi</city>
        <zip>700506</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152366</name>
      <address>
        <city>Oradea</city>
        <zip>410167</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152377</name>
      <address>
        <city>Targu Mures</city>
        <zip>540077</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152370</name>
      <address>
        <city>Timisoara</city>
        <zip>300002</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152369</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <link>
    <url>https://projects7.amedon.de/cgi-bin/WebObjects/AbbVie-HCV-RWE-Prod.woa</url>
    <description>eCRF</description>
  </link>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 20, 2017</lastchanged_date>
  <firstreceived_date>June 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ombitasvir</keyword>
  <keyword>Dasabuvir</keyword>
  <keyword>Paritaprevir</keyword>
  <keyword>HCV</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
